Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Building better therapeutic vaccines for chronic infections

04.07.2005


Study finds that poor T cell responsiveness limits current approaches



In recent years, researchers have become increasingly interested in developing therapeutic vaccines. Most Americans are familiar with prophylactic, or preventive vaccines, which protect an individual from infections; examples include the common pediatric vaccines as well as the flu shot. But therapeutic vaccines are designed instead to be administered to patients who have already acquired chronic infections, such as HIV or hepatitis. These therapeutic vaccines aim to enhance the immune system’s ability to combat an infectious agent, such as a virus. Researchers are also developing therapeutic vaccines to treat a variety of cancers.

But many experimental therapeutic vaccines have thus far fallen short of expectations. Now, scientists at The Wistar Institute and Emory University offer details about what may prevent the immune system from responding effectively to a therapeutic vaccine during a state of chronic infection. Their findings suggest how scientists might alter therapeutic vaccination approaches to make the immune system respond better. Their work is published today in the Journal of Virology.


"In this study, we wanted to look at why therapeutic vaccines are generally less effective than prophylactic vaccines," says E. John Wherry, Ph.D., assistant professor in Wistar’s Immunology Program and lead author of the study. Wherry conducted the research as a postdoctoral fellow in the Emory University laboratory of Rafi Ahmed, Ph.D., before joining Wistar earlier this year. "What we found was that the T cells in the chronically infected mice responded poorly to the vaccine."

Specifically, Wherry says, the T cells failed to proliferate, or expand in number. This failure to proliferate seemed to correlate with a high viral load, which suggests several directions researchers might pursue in improving response to therapeutic vaccines.

"The ongoing stimulus to the immune system that occurs in chronic infection seems to prevent the immune cells from responding optimally to a therapeutic vaccine," Wherry says. "If we could lower viral load before therapeutic vaccination, we might be able to improve efficacy."

The next step for the research, Wherry says, will be to combine therapeutic vaccines with other modalities that either lower viral load or enhance T cell function, particularly the proliferative capacity of T cells. Possible examples include anti-virals that could be given prior to therapeutic vaccination, or a cytokine that might boost the proliferation or survival of responding cells.

Wherry’s group at Wistar is continuing to work on understanding at a fundamental level why the T cell proliferation is poor when a therapeutic vaccine is administered during a state of chronic infection. He is also planning to compare the immune response using different therapeutic vaccine platforms. While Wherry’s primary interest is in chronic infection, he notes that research in this area should inform the design of better therapeutic cancer vaccines as well because many of the deficiencies in immune response are similar whether the antigen confronting the immune system is a virus or a tumor.

In addition to Wherry and senior author Ahmed, the other co-author of the paper is Joseph N. Blattman, Ph.D., of Fred Hutchinson Cancer Research Center. Funding for the work was provided by the National Institutes of Health and the Cancer Research Institute.

Franklin Hoke | EurekAlert!
Further information:
http://www.wistar.org

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>